Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of FN expression significantly inhibited HBV DNA replication and protein synthesis through activating endogenous IFN-α production.
|
27023403 |
2016 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The choice of patients with higher chance of sustained response (SR) to PEG-IFN can be made with pre-treatment and on-treatment factors; recent studies evidenced the role of early drop of serum hepatitis B surface antigen (HBsAg) as predictor of SR.
|
27793564 |
2016 |
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We measured the frequencies of circulating myeloid (mDC) and plasmacytoid (pDC) dendritic cells and IFN-α production along with the expression of DC-SIGN and Toll Like Receptors (TLR's) in HBV patients at different time points.
|
27658394 |
2016 |
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 39 single nucleotide polymorphism loci in 23 genes of the TLR-IFN pathway and four HLA polymorphism loci associated with chronic HBV infection identified by GWAS were selected for genotyping.
|
25469587 |
2015 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, in HBV several retrospective studies yielded conflicting results of the association of IL28B with PEG-IFN-induced treatment response.
|
26284971 |
2015 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hepatitis B serological markers and viral loads were tested every 3 months until 1 year after stopping Peg-IFN therapy.
|
25835020 |
2015 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 212 hepatitis B e antigen (HBeAg)-positive patients treated with PEG-IFN monotherapy were enrolled in this study.
|
24517415 |
2015 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 30 patients with CHB who achieved HBsAg seroclearance following peg-IFN-α therapy and an additional 30 age-, gender-, hepatitis B e antigen (HBeAg) status- and hepatitis B virus genotype-matched patients with CHB without HBsAg seroclearance following peg-IFN-α therapy, were enrolled as a discovery cohort.
|
25324041 |
2015 |
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Single nucleotide polymorphisms and variant expression of some interferon (IFN) genes in individuals with chronic hepatitis B virus (HBV) infection might be related to higher viral load and disease complications.
|
27101083 |
2015 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 210 patients with chronic hepatitis C genotype 1 of high viral load (baseline serum hepatitis C virus RNA > 5.0 log10 IU/mL) were divided into two groups by type of treatment: triple therapy with telaprevir, pegylated-interferon-α (PEG-IFNα), and ribavirin (RBV) for 24 wk (n = 88), or dual therapy with PEG-IFNα and RBV for 48 wk (n = 122).
|
25914481 |
2015 |
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For HBeAg-positive patients and HBeAg-negative patients with genotype D infection, PEG-IFN therapy could be terminated early at week 12 or 24 in primary non-responders defined by the Hepatitis B surface antigen stopping rules.
|
24738850 |
2014 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endogenous HBV-CpG ODNs from the HBV genome induce IFN-α production so that nanoparticle-encapsulated HBV-CpG may act as an HBsAg vaccine adjuvant and may also represent a potent therapeutic agent for the treatment of chronic HBV infection.
|
23907803 |
2014 |
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vitro IFN-λ1 treatment of Hep3B and Huh7 human hepatoma cell lines increased MHC class I expression, activated JAK-STAT signaling pathways, induced IFN-stimulated gene expression, and inhibited hepatitis B surface antigen (HBsAg) expression.
|
24769671 |
2014 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicated that the expression of the innate immune factors MOV10, A3G, and IFN-α is affected by chronic HBV infection.
|
24871977 |
2014 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was conducted to determine whether polymorphisms near or in interferon-lambda (IFN-λs) genes and their receptor genes such as interleukin 28 receptor, alpha (IL28RA) and interleukin 10 receptor, beta (IL10RB) as well as p21-activated kinases 4 (PAK4) and iron/zinc purple acid phosphatase-like protein (PAPL), which are locate upstream of IFN-λs, and lastly the DEPDC5 gene are associated with hepatitis B virus-related liver disease in Han Chinese.
|
25032264 |
2014 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
To explore the predictive role of serum quantitative HBsAg in predicting treatment response towards IFNα-1b in hepatitis B e antigen-positive chronic hepatitis B patients.
|
23411867 |
2013 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We treated 92 chronic hepatitis B patients (44 hepatitis B e antigen [HBeAg]-positive and 48 HBeAg-negative) with HBV DNA > 100,000 copies/ml (> 17,182 IU/ml) with PEG-IFN and adefovir for 48 weeks and followed them up for 2 years.
|
23639931 |
2013 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The main advantages of IFN-α over nucleoside analogues are the absence of resistance and the possibility of immune-mediated clearance of hepatitis B.
|
23286858 |
2013 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, these sustained response rates can be significantly increased by carefully selecting candidates for PEG-IFN therapy based upon baseline ALT and HBV DNA levels, viral genotype and IL28B polymorphisms, by extending PEG-IFN therapy beyond 48 weeks and, most importantly, by applying early on-treatment stopping rules based upon HBsAg kinetics.
|
23286860 |
2013 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extended treatment with PEG IFNα-2a with lamivudine or adefovir for 96 weeks is a promising strategy to achieve high rates of sustainable HBeAg and HBsAg seroconversion and HBV DNA suppression in patients with HBeAg-positive CHB.
|
23615131 |
2013 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the study is to investigate whether SNPs in JAK1 were associated with outcomes of HBV infection and response to IFNα therapy.
|
22901011 |
2012 |
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We confirmed in two independent studies that the combination of HBsAg and HBV DNA levels at week 12 identifies HBeAg-negative patients with a very low chance of SR to either 48 or 96 weeks of PEG-IFN therapy.
|
22245886 |
2012 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that OAS gene variations may play an important role in response to IFN-α and provide a novel strategy for the resolution of HBV infection.
|
21277331 |
2011 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with lower doses and shorter durations, the licensed PEG-IFNα-2a treatment regimen (180 μg/48 weeks) was the most efficacious and beneficial for HBeAg-positive patients predominantly infected with hepatitis B virus genotypes B or C.
|
22045673 |
2011 |
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated whether HBV infection reduced IFN-α-mediated induction of antiviral defense mechanisms in human hepatocytes.
|
21376046 |
2011 |